Gilead Sciences and Galapagos Shutter Their Pulmonary Fibrosis Program

A large part of a $5 billion bet that Gilead Sciences (NASDAQ: GILD) made in 2019 has fallen apart in late clinical-stage development. The bottom fell out from under ziritaxestat, a new drug candidate Gilead Sciences was developing in partnership with Galapagos (NASDAQ: GLPG), whRead MoreMarketsMarkets Feed